Diagnostic Center | September 05, 2025
AstraZeneca’s Baxdrostat proves effective in in Phase III trial for hard-to-control hypertension
The medicine was well tolerated, with no unexpected safety issue
The medicine was well tolerated, with no unexpected safety issue
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
CSPC will receive an upfront payment of $100 million from AstraZeneca
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Subscribe To Our Newsletter & Stay Updated
